■ 60.8% discount to A-shares, wider than five-year average; too high to ignore, opportunity to pounce. Since the start of May, the spread between Tianjin Zhongxin Pharmaceutical Group Corporation’s (TJZX) S-shares (listed on the Singapore Exchange) and its A-shares (listed on the Shanghai Stock Exchange) has been steadily widening. The S-shares are trading at US$1.20 and the A-shares at Rmb19.50 (US$3.06), translating to a 60.8% discount. We believe the discount, which is wider than its five-year average, is too high to ignore and represents an opportunity to pounce.
■ 2018 the start of “multiple times of growth in three years”. TJZX plans to achieve “multiple times of growth in three years, starting from 2018. To get to a good start, it will focus on marketing areas such as: a) developing major product groups, b) building a market-oriented sales system, c) taking the end customer-oriented approach with effective marketing strategies, d) innovating the marketing model to generate onlineoffline synergies, and e) driving scientific research to unleash the potential of its drug portfolio. It will also strengthen quality control and the stability of product safety while working on operational management to drive cost reduction and efficiency enhancement.
■ Realistic plan given increase in price hike of key drug Su Xiao. We believe management’s multi-year growth plan is realistic. With Su Xiao Jiu Xin Pill’s (速效救心丸) price hike set firmly in motion, we are looking at a meaningful impact on 2018 profits and the full impact in 2019. We have already started to see its benefit in 1Q18 as gross margins for the drug manufacturing business increased to beyond 60%, lifting blended gross margin to 41.3% (+6.3 ppt yoy), leading PATMI to grow 29.6% yoy.
Source :UOB KayHian Research